Hemophagocytic lymphohistiocytosis with immunotherapy: Brief review and case report

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Sadaat, Masood ^a   Jang, Sekwon ^a  

^a Inova Schar Cancer Institute   (United States)

Author keywords

BiTe; CAR T; Checkpoint blockade; Cytokine release syndrome; Hemophagocytic lymphohistiocytosis; HLH; Immune checkpoint inhibitors; Ipilimumab; IRAE; Macrophage activation syndrome; Natural killer cells; Nivolumab; PD 1; PDL 1; Pembrolizumab; SCD163

Indexed keywords

CD163 ANTIGEN; LACTATE DEHYDROGENASE; PEMBROLIZUMAB; PREDNISONE; STEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CASE REPORT; CELL FUNCTION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEVER; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOTHERAPY; MALE; METASTATIC MELANOMA; MIDDLE AGED; NATURAL KILLER CELL; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; ADVERSE EVENT; MELANOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; IMMUNOTHERAPY; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MELANOMA; MIDDLE AGED; PREDNISONE;

EID: 85048128875     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0365-3     Document Type: Article

References (29)

1. Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017; https://doi.org/10.1002/cncr.30826.
2. Weitzman S. Approach to Hemophagocytic syndromes. Hematology. 2011;2011(1):178-83. https://doi.org/10.1182/asheducation-2011.1.178.
3. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503-16. https://doi.org/10.1016/S0140-6736(13)61048-X.
4. Ammann S, Lehmberg K, zur SU, et al. Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire. Eur J Immunol. 2017;47(2):364-73. https://doi.org/10.1002/eji.201646686.
5. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6):713-27.
6. Daver N, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol. 2017; https://doi.org/10.1016/S1470-2045(17)30004-9.
7. Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018:1-0. https://doi.org/10.1016/j.beha.2018.03.004.
8. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-74. https://doi.org/10.1093/annonc/mdv623.
9. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of Cancer. Arthritis Rheum. 2017; https://doi.org/10.1002/art.40043.
10. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-20. https://doi.org/10.1002/art.38690.
11. Hejblum G, Lambotte O, Galicier L, et al. A web-based Delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PLoS One. 2014;9(4) https://doi.org/10.1371/journal.pone.0094024.
12. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer. 2008; https://doi.org/10.1002/pbc.
13. Grangé S, Buchonnet G, Besnier E, et al. The use of ferritin to identify critically ill patients with secondary Hemophagocytic Lymphohistiocytosis. Crit Care Med. 2016; https://doi.org/10.1097/CCM.0000000000001878.
14. Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005; https://doi.org/10.1111/j.1600-0609.2004.00318.x.
15. Ness KK, Delany JP, Kaste SC, et al. Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia Key Points; 2015. https://doi.org/10.1182/blood-2015-01.
16. Tamamyan GN, Kantarjian HM, Ning J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016; https://doi.org/10.1002/cncr.30084.
17. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2013; https://doi.org/10.1309/AJCP4ZDKJ4ICOUAT.
18. Otrock ZK, Daver N, Eby CS. Diagnostic challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma, Myeloma Leuk. 2017; https://doi.org/10.1016/j.clml.2017.02.017.
19. Wang Y, Wang Z. Treatment of hemophagocytic lymphohistiocytosis. Curr Opin Hematol. 2017; https://doi.org/10.1097/MOH.0000000000000302.
20. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006;48(2):124-31. https://doi.org/10.1002/pbc.21039.
21. Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411-20. https://doi.org/10.1016/j.blre.2016.05.001.
22. Wang Y, Wang Z, Huang W, et al. Multi-Center Study of DEP Regimen As a Salvage Therapy for Adult Refractory Hemophagocytic Lymphohistiocytosis. Present 56th ASH Annu Meet December 6-9, 2014; San Fr CA Abstr 2748. 2016;126(19):2186-93. https://doi.org/10.3760/cma.j.issn.0253-2727.2014.10.006.
23. Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403. https://doi.org/10.1093/annonc/mdx113.
24. Satzger I, Ivanyi P, Länger F, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab; 2018. https://doi.org/10.1016/j.ejca.2018.01.063.
25. Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ. Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer. 2017; https://doi.org/10.1016/j.ejca.2017.02.016.
26. Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017 https://doi.org/10.1093/annonc/mdw537.
27. Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018. https://doi.org/10.1016/j.drudis.2018.02.012.
28. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (United States). 2014; https://doi.org/10.1097/PPO.0000000000000035.
29. Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018; https://doi.org/10.1212/WNL.0000000000005420 , https://doi.org/10.1212/WNL.0000000000005420.